Alain Delcayre, PhD

SVP, Research

Alain brings a wealth of start-up, scientific team building, and R&D experience to Parvus, much of it in the field of nanoparticle-based immunotherapy research. While at Anosys, Alain’s team pioneered the development of newly discovered nanovesicles, ie exosomes, as cancer immunotherapeutics, and under his leadership, the team went on to discover Exosome Display, a technology now widely used for exosome-based targeted drug delivery. As VP of R&D for the Cancer Division of Bavarian Nordic (formerly BN-ImmunoTherapeutics), Alain built and managed the research team responsible for developing the Company’s poxvirus-based cancer vaccine, PROSTVAC, through Phase 3. Alain received his PhD in Molecular and Cellular Biology at the Université Pierre et Marie Curie (PARIS VI) and completed postdoctoral studies at the California Institute of Biologic Research/Stratagene (La Jolla, CA).